| 证券代码：300759 证券简称：康龙化成 | 公告编号：2025-038 | | --- | --- | | 康龙化成（北京）新药技术股份有限公司 | | | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 | | | 记载、误导性陈述或重大遗漏。 | | | 以下为本公司的 2025 年半年度业绩预告。本业绩预告所载之财务数据未经 | | | 审计，除经调整的非《国际财务报告准则》下归属于上市公司股东的净利润或另 | | | 有注释外，本业绩预告所载之财务数据根据中国企业会计准则编制。 | | | 一、本期业绩预计情况 | | | 预计营业收入、归属于上市公司股东的扣除非经常性损益后的净利润以及经 | | | 调整的非《国际财务报告准则》下归属于上市公司股东的净利润同向上升，预计 | | | 归属于上市公司股东的净利润同向下降。 | | | 项 目 本报告期 上年同期 | | | 营收：633,304.36 万元–650,117.75 万元 | | | 营业收入 营收：560,446.34 万元 | | | 比上年同期增长：13%–16% | | | 归属于上市公司股东 盈利：67 ...

[WuXi AppTec 2025 Half-Year Performance Forecast](index=1&type=section&id=WuXi%20AppTec%20(Beijing)%20Co.%2C%20Ltd.%202025%20Half-Year%20Performance%20Forecast) WuXi AppTec provides its preliminary financial outlook for the first half of 2025, detailing expected changes in key performance indicators [Current Period Performance Forecast](index=1&type=section&id=I.%20Current%20Period%20Performance%20Forecast) The company anticipates year-over-year growth in H1 2025 operating revenue, net profit excluding non-recurring gains/losses, and adjusted non-IFRS net profit, while net profit attributable to shareholders is expected to decline by 36%-39% due to significant non-recurring gains in the prior year Key Financial Indicators for H1 2025 Performance Forecast | Item | Current Period (2025H1) | Prior Period (2024H1) | Change | | :--- | :--- | :--- | :--- | | **Operating Revenue** | RMB 6,333.0436 million - RMB 6,501.1775 million | RMB 5,604.4634 million | Growth 13%–16% | | **Net Profit Attributable to Shareholders** | RMB 679.1758 million - RMB 712.5779 million | RMB 1,113.4030 million | Decline 36%–39% | | **Net Profit Excluding Non-Recurring Gains/Losses** | RMB 624.2831 million - RMB 647.5772 million | RMB 465.8829 million | Growth 34%–39% | | **Adjusted Non-IFRS Net Profit** | RMB 731.6822 million - RMB 766.1955 million | RMB 690.2662 million | Growth 6%–11% | | **Basic Earnings Per Share** | RMB 0.3858 - RMB 0.4048/share | RMB 0.6282/share | - | - The company estimates H1 2025 non-recurring gains/losses attributable to shareholders to be approximately **RMB 60 million to RMB 70 million**, primarily comprising government subsidies, fair value changes in financial assets, and wealth management product gains/losses[7](index=7&type=chunk) - The company uses **adjusted non-IFRS net profit** as a supplementary financial metric, excluding the impact of share-based payments, exchange gains/losses, equity investment gains/losses, convertible bond-related gains/losses, and other incidental or non-operating items, to better assess core business performance[8](index=8&type=chunk) [Communication with Accounting Firm](index=3&type=section&id=II.%20Communication%20with%20Accounting%20Firm) This performance forecast has not been audited or pre-audited by an accounting firm - This performance forecast has not been audited or pre-audited by an accounting firm[10](index=10&type=chunk) [Explanation of Performance Changes](index=3&type=section&id=III.%20Explanation%20of%20Performance%20Changes) Performance changes are primarily driven by robust core business growth and a significant year-over-year decrease in non-recurring gains/losses, impacting net profit attributable to shareholders - The company steadfastly implements its core strategy of **'full-process, integrated, internationalized, multi-therapy'**, driven by customer needs, deepening global presence, and strengthening technology platforms to achieve sustained core business growth[11](index=11&type=chunk) - Non-recurring gains/losses for the reporting period are estimated at **RMB 60 million to RMB 70 million**, a significant year-over-year decrease of approximately **RMB 580 million** compared to **RMB 647.5201 million** in the prior period (primarily from the disposal of PROTEOLOGIX, INC. equity), which is the main reason for the decline in net profit attributable to shareholders[11](index=11&type=chunk) - Despite the decline in net profit attributable to shareholders, core operating indicators show strong performance, with Q2 2025 operating revenue growing by **13.11%**, net profit excluding non-recurring gains/losses by **23.33%**, and adjusted non-IFRS net profit by **13.67%** based on the forecast median[11](index=11&type=chunk) [Other Relevant Information](index=3&type=section&id=IV.%20Other%20Relevant%20Information) The company advises investors that this performance forecast is a preliminary, unaudited estimate by the finance department, with detailed financial data to be disclosed in the 2025 half-year report on the Shenzhen and Hong Kong stock exchanges, urging caution regarding investment risks - This performance forecast data represents a preliminary, unaudited estimate by the company's finance department[13](index=13&type=chunk) - Detailed H1 2025 performance data will be disclosed in the official reports published by the company on the Shenzhen Stock Exchange and Hong Kong Stock Exchange[14](index=14&type=chunk) [Reference Documents](index=4&type=section&id=V.%20Reference%20Documents) Reference documents for this announcement include the Board of Directors' explanation regarding the performance forecast and other documents required by the Shenzhen Stock Exchange - Reference documents include: - Board of Directors' explanation regarding the current period's performance forecast - Other documents required by the Shenzhen Stock Exchange[15](index=15&type=chunk)

康龙化成（300759）公告，信息披露义务人信中康成及其一致行动人信中龙成合计减持公司股份5521.3 万股，占公司总股本的3.36%。此次减持包括集中竞价交易和大宗交易两种方式，减持期间为2023年1 月10日至2025年7月9日。此次减持是由于信息披露义务人自身资金需求以及公司历次激励计划归属的限 制性股票上市、回购注销股份、权益分派等原因导致股份比例被动变动。未来12个月内，信息披露义务 人将继续减持股份并计划在未来12个月内无增持计划。 ...

证券代码：300759 证券简称：康龙化成 公告编号：2025-037 康龙化成（北京）新药技术股份有限公司 关于持股 5%以上股东权益变动 触及 1%和 5%整数倍的提示性公告 公司持股 5%以上股东深圳市信中康成投资合伙企业（有限合伙）及其一致行 动人深圳市信中龙成投资合伙企业（有限合伙）保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 康龙化成（北京）新药技术股份有限公司（以下简称"公司"）于近日收到 公司持股 5%以上股东深圳市信中康成投资合伙企业（有限合伙）（以下简称"信 中康成"）及其一致行动人深圳市信中龙成投资合伙企业（有限合伙）（以下简称 "信中龙成"）出具的《股份减持进展告知函》，获悉信中康成和信中龙成因减持、 公司总股本变动等原因导致权益变动触及 1%和 5%的整数倍。现将有关情况公 告如下： 1.基本情况 信息披露义务人 （一） 深圳市信中康成投资合伙企业（有限合伙） 住所 深圳市前海深港合作区南山街道兴海大道 3046 号香江金 融大厦 1314-B8 信息披露义务人 （二） 深圳市信 ...

康龙化成（北京）新药技术股份有限公司 简式权益变动报告书 上市公司名称：康龙化成（北京）新药技术股份有限公司 股票上市地点：深圳证券交易所（A股）、香港联合交易所（H股） 股票简称：康龙化成（A股、H股） 股票代码：300759.SZ/03759.HK 信息披露义务人（一）：深圳市信中康成投资合伙企业（有限合伙） 住所：深圳市前海深港合作区南山街道兴海大道3046号香江金融大厦1314-B8 通讯地址：北京市朝阳区京城大厦16层 信息披露义务人（二）：深圳市信中龙成投资合伙企业（有限合伙） 住所：深圳市前海深港合作区前湾一路1号A栋201室（入驻深圳市前海商务秘 书有限公司） 通讯地址：北京市朝阳区京城大厦16层 签署日期：2025年7月9日 2 1 信息披露义务人声明 一、本报告书依据《中华人民共和国证券法》《上市公司收购管理办法》 《公开发行证券的公司信息披露内容与格式准则第15号—权益变动报告书》 （以下简称"《准则15号》"）及相关的法律、法规和规范性文件编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不 违反信息披露义务人合伙协议或内部规则中的任何条款，或与之相冲突。 三、依据 ...

Group 1 - The core point of the news is the performance and holdings of the China Europe Medical Health Mixed Fund C, which has shown a recent net value increase of 0.94% but a one-month return of -0.94% [1] - The fund's three-month return is 16.34%, ranking 306 out of 1238 similar funds, while its year-to-date return is 10.10%, ranking 434 out of 1218 [1] - The top ten stock holdings of the fund account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%) and WuXi AppTec (9.95%) [1] Group 2 - The China Europe Medical Health Mixed Fund C was established on September 29, 2016, and as of March 31, 2025, it has a total scale of 15.566 billion yuan [1] - The fund is managed by two key managers: Ms. Ge Lan, who has been managing it since its inception, and Ms. Zhao Lei, who took over management on July 4, 2025 [2]

致：香港交易及結算所有限公司 公司名稱: 康龍化成（北京）新藥技術股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年7月7日 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年6月30日 狀態: 新提交 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03759 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 301,537,125 | RMB | | 1 RMB | | 301,537,125 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 301,537,125 | RMB | | 1 RMB | | 301,537,125 | | ...

Summary of Conference Call Records Industry Overview - The innovative drug industry chain is gradually stabilizing and recovering, with CXO orders rebounding since last year, leading to strong mid-year performance in key segments [1][2][3] - The overall trend for the pharmaceutical sector in Q2 2025 is positive, particularly in innovative drugs and their supply chains, despite recent market fluctuations [2][3] Key Companies and Performance - **Hengrui, Huadong, and China Biopharmaceutical** are expected to achieve double-digit growth in Q2 and for the entire year [1][6] - **WuXi AppTec** aims for a revenue target of 43 billion, with an expected growth of over 15% and faster net profit growth; **WuXi AppTec's** revenue growth is projected at over 35% for the year [1][11] - **Kelaiying** anticipates a revenue growth of over 15% for the year, while **Kanglong Huacheng** expects around 10% growth in revenue and profit for Q2 [1][11][13] - **BaiPuSi and Haoyuan Pharmaceutical** are performing well, with most companies expecting revenue growth of over 20% [1][15] Market Catalysts - Recent adjustments in medical insurance policies and industry conferences (WCLC, ESMO, Ash) are seen as potential catalysts for growth in the innovative drug sector [1][7][9] - The upcoming medical insurance negotiations and directory adjustments are expected to be significant driving forces in the second half of the year [9][10] Investment Opportunities - Despite a recent decline in market sentiment, large-cap companies like **BaiJi, Hengrui, XinDa, Kangfang, and Shiyao** are recommended for investment, along with smaller companies like **Dizhe and Yifangzejin** [10] - The CXO and upstream sectors are highlighted as key investment areas, with strong performance expected due to improved orders and geopolitical factors [19][20] Sector Performance - The medical device sector is still in a clearing inventory phase, with some companies showing good growth, particularly in overseas markets [17][18] - The OTC and traditional Chinese medicine sectors have not shown significant improvement but may see recovery in the second half of the year [5][18] Future Outlook - The overall outlook for the second half of 2025 remains optimistic, with expectations of continued growth in the innovative drug sector and supportive external factors [9][24] - The domestic financing environment is expected to improve, with a notable increase in activity anticipated in the latter half of the year [26][38] Conclusion - The innovative drug industry chain, particularly the CXO segment, is positioned for strong growth, supported by favorable market conditions and strategic company performances. Investors are encouraged to focus on key players within this sector for potential opportunities.

Core Viewpoint - 康龙化成's management structure has undergone changes, particularly regarding the voting rights and equity ownership among its key executives, which may impact the company's governance and decision-making processes [1][2][3] Group 1: Management Changes - The voting rights agreement established by the company's chairman, CEO, and COO ensures that they act in concert regarding any proposals presented to the board and shareholders [1] - 郑北 has stepped down as a general partner of the employee stockholding platforms, leading to a redistribution of voting rights associated with the A-shares held by these platforms [2] Group 2: Equity Ownership - Following the changes in general partners, the combined equity ownership of 楼柏良, 楼小强, and 郑北 in the company decreased from approximately 19.36% to 18.18% [3]

Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Health Mixed A Fund, which has shown a net value increase of 1.77% recently and a year-to-date return of 8.30% [1] - The fund's recent one-month return is 0.30%, with a six-month return of 8.30%, ranking 628 out of 1722 in its category for both periods [1] - The top ten stock holdings of the fund account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%) and WuXi AppTec (9.95%) [1] Group 2 - The China Europe Medical Health Mixed A Fund was established on September 29, 2016, and has a total scale of 15.613 billion yuan as of March 31, 2025 [1] - The fund is managed by Guo Lan, who has extensive experience in the investment management field, having previously worked at various financial institutions [2]